SingleMetabolic / GLP-1

Tirzepatide 15mg

Dual GLP-1/GIP receptor agonist investigated for substantial glycemic management, food intake suppression, and metabolic body weight modulation.

Mechanism

Engages both GLP-1 and GIP incretin receptors simultaneously to stimulate glucose-mediated insulin secretion, attenuate glucagon output, decelerate gastric digestion, and blunt central appetite signals.

Dosing

Initial research protocols document an introductory exposure of 2.5 mg administered subcutaneously once every 7 days.

Reconstitution

Reconstituting the 15 mg vial with 2.0 mL of bacteriostatic water yields an operational working concentration of 7.5 mg/mL.

Storage

Store the unmixed lyophilized powder at -20°C; following reconstitution, maintain between 2°C and 8°C away from light and utilize within 2 to 4 weeks.

Mix & measure Tirzepatide 15mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Tirzepatide 15mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration7.50mg/mL

Draw volume0.333mL

On the syringe33.3units

Total doses in vial: 6.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	2.5 mg once weekly	33 units (0.33 mL) × 1 injection
Weeks 5–8	5 mg once weekly	67 units (0.67 mL) × 1 injection
Weeks 9–12	7.5 mg once weekly	100 units (1.0 mL) × 1 injection
Weeks 13–16	10 mg once weekly	67 units (0.67 mL) × 2 injections

Reconstitution Steps

1
Aspirate 2.0 mL of sterile bacteriostatic water using a fresh syringe.
2
Introduce the diluent slowly down the interior glass wall of the 15 mg vial to avoid agitation and foaming.
3
Gently rotate or roll the vial until the lyophilized cake is fully dissolved, strictly avoiding vigorous shaking.
4
Record the date of preparation on the vial label and place in refrigerated storage at 2–8 °C protected from light.

Supplies Needed

Peptide Vial

Lyophilized Tirzepatide 15 mg cake for reconstitution

Insulin Syringes (U-100)

Calibrated 1 mL syringes utilized for precise measurement and subcutaneous administration

Bacteriostatic Water

Preserved sterile diluent required to reconstitute the peptide cake

Alcohol Swabs

Disinfecting vial rubber septums and test site barriers prior to access

Why researchers study it

Weight loss & obesity

Blood sugar & glycemic control

Appetite & food intake

Cardiometabolic markers

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Tirzepatide represents a prominent therapeutic candidate within metabolic science, operating as a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways. By acting across these dual incretin mechanisms, scientific models observe enhanced beta-cell responsiveness alongside significant delays in gastrointestinal transit time, leading to suppressed energy intake. In extensive preclinical and human clinical study cohorts, this unified receptor activation yields substantial improvements in glycated hemoglobin concentrations and pronounced mass reduction compared to monotherapy incretins. Its engineered pharmacokinetic stability delivers a half-life of roughly six days, enabling researchers to maintain sustained exposure through weekly subcutaneous delivery models. Research environments regularly evaluate graduated escalation schedules to assess systemic tolerance while examining metabolic parameters. The 15 mg lyophilized format provides an adaptable platform for investigators charting low-dose introductory phases up through advanced maintenance endpoints.

References

1.SURMOUNT program, New England Journal of Medicine, 2023 — Once-Weekly Tirzepatide for Weight Management (72-week results)
2.SURMOUNT obesity trials, JAMA Network, 2023 — Efficacy and safety data (~20% weight loss at 15 mg weekly)
3.Phase 2 trial, The Lancet, 2023 — Tirzepatide in type 2 diabetes: weight loss and glycemic outcomes at 36 weeks
4.PubMed / NEJM, 2023 — Tirzepatide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events
5.Review, Metabolites (PMC), 2025 — Tirzepatide—A Game Changer in Obesity Pharmacotherapy (mechanism and trials)
6.SURMOUNT-1, New England Journal of Medicine, 2022 — Tirzepatide once weekly for the treatment of obesity
7.Meta-analysis, PubMed, 2025 — Tirzepatide achieves ~14% greater weight reduction vs placebo with no increase in adverse events
8.Molecular Metabolism, 2025 — Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics
9.Nature Reviews Endocrinology, 2024 — Dual GIP/GLP-1 receptor agonists for obesity and diabetes: a clinical landscape review
10.Journal of Cachexia, Sarcopenia and Muscle (PMC), 2020 — Protein requirements during weight loss: preserving lean mass
11.GenScript Technical Bulletin, 2024 — Peptide Storage and Handling Guidelines for lyophilized and reconstituted peptides
12.Bachem Knowledge Center, 2024 — Handling and Storage Guidelines for Peptides: stability and freeze-thaw cycles
13.CDC Guidance, 2024 — Vaccine Administration: Subcutaneous Injection technique, angle, and site guidance
14.NCBI Bookshelf, 2024 — Injection Administration Best Practices: aseptic technique, sharps disposal, and safety
15.PMC Review, 2019 — Pharmacologic Considerations of the Subcutaneous Route: injection technique and site rotation to prevent lipohypertrophy